Genome Foundation Profile
Key Indicators
- Paid Up Capital ₹ 8.15 M
as on 22-12-2024
- Company Age 20 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 62.04%
(FY 2022)
- Profit -53.96%
(FY 2022)
- Ebitda -568.20%
(FY 2022)
- Net Worth 520.06%
(FY 2022)
- Total Assets 219.82%
(FY 2022)
About Genome Foundation
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.00 and a paid-up capital of Rs 8.15 M, as per Ministry of Corporate Affairs (MCA) records.
Satyanarayana Jeedigunta, Deep Adla, Reddanna Pallu, and Ten other members serve as directors at the Company.
- CIN/LLPIN
U73200TG2004NPL043436
- Company No.
043436
- Company Classification
Private Not For Profit Company
- Incorporation Date
09 Jun 2004
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Genome Foundation?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Poorna Kaza  | Managing Director | 09-Jun-2004 | Current |
Board Members(12)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Reddanna Pallu | Director | 27-Sep-2024 | Current |
| Appa Podile | Director | 02-Apr-2022 | Current |
| Satyanarayana Jeedigunta | Director | 15-Jul-2020 | Current |
| Deep Adla | Director | 27-Sep-2024 | Current |
| Kosaraju Rao | Director | 15-Jul-2020 | Current |
| Veera Bhushanam | Director | 27-Sep-2024 | Current |
Financial Performance of Genome Foundation.
Genome Foundation, for the financial year ended 2022, experienced significant growth in revenue, with a 62.04% increase. The company also saw a substantial fall in profitability, with a 53.96% decrease in profit. The company's net worth Soared by an impressive increase of 520.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genome Foundation?
Unlock access to Genome Foundation's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genome Foundation?
Unlock and access historical data on people associated with Genome Foundation, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genome Foundation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genome Foundation's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
